is folic acid effective and safe with a TT genotype

The short version: the TT genotype is a real disadvantage, but folic acid pills carry their own risks, and the evidence that supplemental folic acid changes hard outcomes (like fracture or stroke) for TT carriers is thin.

The MTHFR C677T TT genotype reduces the enzyme's activity. People with TT have higher homocysteine, lower bone density (about 3% less at the spine versus CC), and roughly 2.6 times the fracture risk over five years in one Danish study [26]. They also carry a doubled risk of neural tube defects in the embryo [34] and a higher risk of placental abruption in pregnancy [38]. These are real burdens. The folate system is indeed compromised.

Folic acid pills do lower homocysteine. In a 1999 trial of coronary artery disease patients, 400 mcg of folic acid per day cut homocysteine from 14 to about 10 µmol/L within a month [15]. That is a real biochemical effect. But the leap from "lower homocysteine" to "fewer heart attacks, strokes, or fractures" is where the evidence falls apart. A 2012 meta-analysis of 26 trials and nearly 59,000 people found that folic acid supplementation as a supplement (not grain fortification) did not reduce cardiovascular disease or all-cause mortality at all [23]. The only hint of benefit was a 7% relative reduction in stroke, but that disappeared in countries with mandatory grain fortification — which includes the US and Canada. The B-PROOF trial in elderly adults showed that even with a 28% drop in homocysteine from vitamin B12 plus folic acid, biomarkers of inflammation and endothelial function did not improve [11].

The other concern is unmetabolized folic acid. Synthetic folic acid is not the natural form (5-MTHF). In a 2021 study of Canadian children taking 1 mg folic acid daily, every single child had unmetabolized folic acid in their blood, and 64% had elevated total folate [8]. A 2022 study proposed that the photoproducts of folic acid can block MAIT cell activation [25], a mechanism that could explain immune side effects. People with TT already process folate less efficiently, which means they may accumulate more unmetabolized folic acid for any given dose.

The bottom line: if you have the TT genotype and want to lower homocysteine, methylfolate (5-MTHF) is the more logical choice — it bypasses the defective MTHFR enzyme, does not require conversion, and carries none of the risk of unmetabolized folic acid accumulation [25]. The evidence for the standard recommendation of 400-800 mcg folic acid in TT is limited to surrogate endpoints (homocysteine drops) with no demonstration that it improves the outcomes that matter: fewer fractures, fewer strokes, healthier pregnancies. And the larger trials that do exist for folic acid in the general population show no benefit for cardiovascular disease and no improvement in inflammation or vessel health [11, 23].

My call: folic acid supplementation in TT carriers lowers homocysteine but the evidence does not show it prevents the hard outcomes (fractures, strokes, adverse pregnancy events) that actually drive the concern, and it carries the distinct risk of accumulating unmetabolized folic acid. Methylfolate is the safer bet. Confidence: moderate — the homocysteine-lowering is well-demonstrated, but the leap to clinical benefit for TT carriers has never been properly tested.